JP2022510410A5 - - Google Patents
Info
- Publication number
- JP2022510410A5 JP2022510410A5 JP2021531722A JP2021531722A JP2022510410A5 JP 2022510410 A5 JP2022510410 A5 JP 2022510410A5 JP 2021531722 A JP2021531722 A JP 2021531722A JP 2021531722 A JP2021531722 A JP 2021531722A JP 2022510410 A5 JP2022510410 A5 JP 2022510410A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- item
- composition according
- subject
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862776985P | 2018-12-07 | 2018-12-07 | |
| US62/776,985 | 2018-12-07 | ||
| US201962909147P | 2019-10-01 | 2019-10-01 | |
| US62/909,147 | 2019-10-01 | ||
| US201962926390P | 2019-10-25 | 2019-10-25 | |
| US62/926,390 | 2019-10-25 | ||
| PCT/US2019/065069 WO2020118252A1 (en) | 2018-12-07 | 2019-12-06 | Methods for treating castration-resistant and castration- sensitive prostate cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022510410A JP2022510410A (ja) | 2022-01-26 |
| JP2022510410A5 true JP2022510410A5 (https=) | 2022-11-29 |
Family
ID=70974424
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021531722A Pending JP2022510410A (ja) | 2018-12-07 | 2019-12-06 | 去勢抵抗性および去勢感受性前立腺がんを処置するための方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20200281949A1 (https=) |
| EP (1) | EP3891294A4 (https=) |
| JP (1) | JP2022510410A (https=) |
| KR (1) | KR20210100145A (https=) |
| CN (1) | CN113164500A (https=) |
| AU (1) | AU2019395100A1 (https=) |
| CA (1) | CA3120850A1 (https=) |
| MX (1) | MX2021005075A (https=) |
| WO (1) | WO2020118252A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016141458A1 (en) | 2015-03-12 | 2016-09-15 | British Columbia Cancer Agency Branch | Bisphenol ether derivatives and methods for using the same |
| KR102608921B1 (ko) | 2015-05-18 | 2023-12-01 | 스미토모 파마 온콜로지, 인크. | 생체 이용률이 증가된 알보시딥 프로드러그 |
| US20170298033A1 (en) | 2016-04-15 | 2017-10-19 | The University Of British Columbia | Bisphenol derivatives and their use as androgen receptor activity modulators |
| WO2018094275A1 (en) | 2016-11-18 | 2018-05-24 | Tolero Pharmaceuticals, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
| JP7196160B2 (ja) | 2017-09-12 | 2022-12-26 | スミトモ ファーマ オンコロジー， インコーポレイテッド | Ｍｃｌ－１阻害剤アルボシジブを用いた、ｂｃｌ－２阻害剤に対して非感受性である癌の治療レジメン |
| US20190240198A1 (en) * | 2018-02-05 | 2019-08-08 | Dean G. Tang | Formulations and methods for the treatment of cancers |
| US11034710B2 (en) | 2018-12-04 | 2021-06-15 | Sumitomo Dainippon Pharma Oncology, Inc. | CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer |
| WO2020191326A1 (en) | 2019-03-20 | 2020-09-24 | Sumitomo Dainippon Pharma Oncology, Inc. | Treatment of acute myeloid leukemia (aml) with venetoclax failure |
| WO2020198712A1 (en) | 2019-03-28 | 2020-10-01 | Essa Pharma, Inc. | Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof |
| CN115916170A (zh) | 2020-04-17 | 2023-04-04 | 埃萨制药股份有限公司 | 固体形式的n-末端结构域雄激素受体抑制剂及其用途 |
| US20240207264A1 (en) * | 2021-04-16 | 2024-06-27 | Essa Pharma Inc. | Pharmaceutical compositions comprising inhibitors of the androgen receptor and uses thereof |
| WO2023114264A1 (en) * | 2021-12-15 | 2023-06-22 | Eli Lilly And Company | Combination for treatment of high-risk metastatic hormone-sensitive prostate cancer |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001080896A2 (en) * | 2000-04-21 | 2001-11-01 | Arch Development Corporation | Flavopiridol drug combinations and methods with reduced side effects |
| AU2013323736A1 (en) * | 2012-09-26 | 2015-04-09 | Mannkind Corporation | Multiple kinase pathway inhibitors |
| PL2945628T3 (pl) * | 2013-01-15 | 2020-09-21 | Aragon Pharmaceuticals, Inc. | Modulator receptorów androgenowych w skojarzeniu z octanem abirateronu i prednizonem do leczenia nowotworu stercza |
| CA2959336A1 (en) * | 2014-08-25 | 2016-03-03 | The Johns Hopkins University | Methods and compositions related to prostate cancer therapeutics |
| KR102608921B1 (ko) * | 2015-05-18 | 2023-12-01 | 스미토모 파마 온콜로지, 인크. | 생체 이용률이 증가된 알보시딥 프로드러그 |
| WO2018094275A1 (en) * | 2016-11-18 | 2018-05-24 | Tolero Pharmaceuticals, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
| US11034710B2 (en) * | 2018-12-04 | 2021-06-15 | Sumitomo Dainippon Pharma Oncology, Inc. | CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer |
-
2019
- 2019-12-06 CA CA3120850A patent/CA3120850A1/en active Pending
- 2019-12-06 US US16/706,463 patent/US20200281949A1/en not_active Abandoned
- 2019-12-06 KR KR1020217020796A patent/KR20210100145A/ko not_active Withdrawn
- 2019-12-06 CN CN201980080943.0A patent/CN113164500A/zh active Pending
- 2019-12-06 MX MX2021005075A patent/MX2021005075A/es unknown
- 2019-12-06 JP JP2021531722A patent/JP2022510410A/ja active Pending
- 2019-12-06 AU AU2019395100A patent/AU2019395100A1/en not_active Abandoned
- 2019-12-06 WO PCT/US2019/065069 patent/WO2020118252A1/en not_active Ceased
- 2019-12-06 EP EP19893131.3A patent/EP3891294A4/en not_active Withdrawn
-
2021
- 2021-12-10 US US17/547,799 patent/US20220339172A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022510410A5 (https=) | ||
| Markman | Managing taxane toxicities | |
| RU2587013C2 (ru) | Комбинированная химиотерапия | |
| JP2020516646A5 (https=) | ||
| JP2019529581A5 (https=) | ||
| JP2020517696A5 (https=) | ||
| JP2012522837A5 (https=) | ||
| CN115025090A (zh) | 喹啉衍生物用于治疗食管癌的用途及其治疗方法、药物组合物和试剂盒 | |
| JP2009536956A (ja) | 抗癌治療法 | |
| CN117881396A (zh) | 用螺甾内酯和酰基富烯的组合治疗癌症 | |
| KR20240006610A (ko) | 다중-키나제 억제제의 제약 조성물 및 용도 | |
| JP2020536055A5 (https=) | ||
| Hainsworth et al. | Paclitaxel, carboplatin, and extended schedule etoposide in the treatment of small cell lung carcinoma | |
| CA2525277A1 (en) | Method for augmenting the antitumor activity of anti-cancer agents | |
| JP2020517739A (ja) | リンパ節陽性の初期ホルモン受容体陽性かつヒト上皮成長因子受容体２陰性乳癌の補助治療のための内分泌療法とアベマシクリブとの組み合わせ | |
| JP2024540044A5 (https=) | ||
| Köppler et al. | Dose reduction of steroid premedication for paclitaxel: no increase of hypersensitivity reactions | |
| EP4087572A1 (en) | Combination therapy for treating cancer | |
| AU2024334390A1 (en) | Anti-tumor use of act001 composition | |
| WO2022165056A1 (en) | Treating cancer in patient with pten inactivating mutation | |
| KR20240046527A (ko) | 암치료를 위한 신규 경구용 약학적 조성물 | |
| JPH09506902A (ja) | 前立線癌の化学療法剤の補助剤 | |
| RU2020126340A (ru) | Способы и комбинированное терапевтическое средство для лечения рака | |
| CN109106720B (zh) | 西达本胺与依西美坦在制备用于治疗乳腺癌的联合用药物中的用途及联合用药物 | |
| RU2806635C2 (ru) | Комбинированная терапия, включающая соединение ацилтиомочевины и абиратерон |